#United States #Burlington #pancreatic cancer #Azenta #PRECEDE Foundation

Azenta Life Sciences and PRECEDE Foundation's Partnership for Pancreatic Cancer

Azenta, Inc., listed on Nasdaq under the ticker AZTA, has entered into a significant strategic partnership with the PRECEDE Foundation. This collaboration aims to advance the early detection and prevention of pancreatic cancer, an aggressive disease that claims the lives of many each year in the United States. The announcement was made on November 4, 2025, marking a pivotal moment in the battle against a cancer type notorious for its low survival rates.

Pancreatic cancer is alarmingly the third-most common cause of cancer-related deaths in the United States. More than 66,500 people receive a diagnosis each year, but less than 15,000 survive, resulting in a stark five-year survival rate of only 13%. This statistic falls drastically below other prevalent cancers, such as prostate cancer at 97%, breast cancer at 91%, and colon cancer at 65%. The primary factor contributing to such poor outcomes is the lack of effective early detection methods for pancreatic cancer.

The PRECEDE Foundation, known as the Pancreatic Cancer Early Detection Consortium, has made it its mission to alter this distressing trend. This organization seeks not only to enhance screening and risk assessment tools but also to significantly improve prevention efforts for those at hereditary risk of developing this devastating form of cancer. Their ambitious goal is to boost the five-year survival rate from 13% to an impressive 50% over the next ten years.

The partnership with Azenta will facilitate critical advances in this mission. Azenta’s role involves providing secure access to its biorepository for the storage of study samples, alongside optimizing logistics so that PRECEDE researchers can focus tirelessly on diagnostics improvements. “Early detection is the key to survival in pancreatic cancer,” stated Kathi Shea, Azenta's Chief Client Solutions Officer. She expressed pride in supporting PRECEDE's innovative work by managing their vital samples, thereby enabling ongoing research efforts.

By overseeing these samples, Azenta is positioned to significantly contribute to the development of vital tools and strategies to ensure earlier diagnosis, potentially saving thousands of lives annually. This collaboration emphasizes Azenta’s strategic importance and commitment within the expanding biorepository landscape meant for clinical and diagnostic research.

Moreover, Azenta’s deep global expertise in sample management will assure the continuity and integrity of PRECEDE's research endeavors, allowing researchers to concentrate on discovering breakthroughs and innovations in early cancer detection.

The PRECEDE Foundation, which plans to convene its Annual Meeting this November, will gather international authorities in the field to share insights and explore further collaborative approaches. Those interested in learning more about the PRECEDE Foundation's mission and ongoing initiatives are encouraged to visit their website at www.precedefoundation.org.

About PRECEDE Consortium

The PRECEDE Consortium is an international alliance of experts from various industries and institutions working towards increasing the survival rates of pancreatic cancer patients. Comprising over 60 prestigious academic medical centers worldwide, the consortium boasts the largest cohort of high-risk patients while harnessing longitudinal clinical data to track biospecimens effectively. This collective expertise is pivotal in advancing detection techniques for pancreatic cancer at the earliest possible stages.

About PRECEDE Foundation

The PRECEDE Foundation plays a crucial role in supporting the consortium through fundraising and building necessary infrastructure. Their mission focuses on raising public and financial support to further PRECEDE's goals surrounding improved early detection and the overall survival rate for pancreatic cancer.

About Azenta Life Sciences

Azenta, Inc. is a premier global provider of life science solutions, empowering various organizations to bring crucial therapies and innovations to market efficiently. The company offers a comprehensive package of reliable cold-chain sample management solutions alongside multiomics services geared towards drug development, clinical trials, and advanced cell therapies. Azenta’s products and services are recognized and utilized by leading pharmaceutical, biotech, academic, and healthcare institutions around the world. Headquartered in Burlington, Massachusetts, Azenta operates facilities across North America, Europe, and Asia, demonstrating its commitment to enhancing life science through innovative solutions and partnerships.